A double-blind placebo controlled randomized parallel-group phase 1-2 proof-of-concept clinical trial on efficacy and safety of Sri Weera Badhra Dhamma Prathishakthi Jeewa Panaya© for asymptomatic patients or patients with mild to moderate COVID-19.

Ministry of Production, Supply and Regulation of Pharmaceuticals0 个研究点开始时间: 待定最近更新: 2024年8月20日

适应症

试验速览

暂无简介。

•1. All consenting male and female adults (18–80 years of age)
•2. Asymptomatic or mild or moderate disease (as defined in the case definition)
•3. Two positive RT-qPCR tests
•4. Negative antibody test
•5. Cycle threshold (Ct) value <38 at the time of recruitment
•Case definition: US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research, Centre for Biologics Evaluation and Research. COVID-19: Developing Drugs and Biological Products for Treatment or Prevention Guidance for Industry. 2020;(May):1–11.

•1. Pregnant (known pregnancy or positive urine strip test) and lactating females
•2. Patients who have ingested Sri Weera Badhra Dhamma Prathishakthi Jeewa Panaya© within the past six weeks
•3. Patients with known allergy to the individual ingredients (Bees honey, nutmeg, fennel, raw ginger) of Sri Weera Badhra Dhamma Prathishakthi Jeewa Panaya©
•4. Any diagnosed co-morbidity such as diabetes, hypertension, renal disease, liver disease or bronchial asthma.

发起方

Ministry of Production, Supply and Regulation of Pharmaceuticals